The FDA reverses its ban on Juul e-cigarettes

The FDA reverses its ban on Juul e-cigarettes


Juul packages are seen on a shelf at Empire Smoke Shop on December 07, 2022 in the Flatbush neighborhood of Brooklyn borough in New York City. 

Michael M. Santiago | Getty Images

The Food and Drug Administration announced Thursday that it has reversed its ban on Juul e-cigarettes while it reviews new court decisions and considers updated information provided by the vape maker.

The FDA first ordered the company to stop selling its products in 2022, but they have stayed on shelves pending an appeal. Juul has maintained its status as the No. 2 e-cigarette maker in the U.S. during this time.

Now, the FDA says Juul’s products are back under agency review — although it emphasized that this new status was not an indication they would be fully cleared.

It said federal statutes barred it from disclosing additional information.

Juul became one of the highest-profile successes of the initial burst in e-cigarette use more than a decade ago. That success was beset by concerns that e-cigarettes were introducing a new generation of people to nicotine addiction. Vaping reached a peak of approximately 28% among all high school students in 2019, according to the Centers for Disease Control and Prevention.

While Juul has since entered a period of financial retrenchment, sales of e-cigarettes and other alternative nicotine products have continued to grow.

Last year, the Centers for Disease Control and Prevention reported e-cigarette use had grown nearly 50% between January 2020 and December 2022. During that period, the agency said, Juul trailed only Vuse among e-cig brands.

Now there are signs e-cigarette growth is being surpassed by smokeless tobacco products.

Philip Morris, which now owns nicotine pouch-maker Zyn, recently reported that its smokeless category increased 21% from a year ago and that it now accounts for nearly 40% of the firm’s total revenue, Barron’s reported.

In a statement, Juul said it appreciated the FDA’s latest decision, adding it now looks forward to “re-engaging with the agency on a science- and evidence-based process to pursue a marketing authorization” for its products.

“We remain confident in the quality and substance of our applications and believe that a full review of the science and evidence will demonstrate that our products meet the statutory standard of being appropriate for the protection of public health,” the company said.

Even as Juul has pursued its appeal of the 2022 ban, that initial FDA ruling significantly disrupted the company’s finances, prompting a bailout from two of its largest investors, The Wall Street Journal has reported.

To date, the FDA has given only 23 e-cigarette products, made by just three companies, official approval to be marketed to consumers.



Source

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill
Health

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill

Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A closely watched pill from […]

Read More
Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat
Health

Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images Cattle ranchers in Texas and around the country […]

Read More
Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost
Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.  Claude for Life Sciences is […]

Read More